Condition: Renal Cell Carcinoma (Kidney Cancer) · Metastatic Renal Cell Carcinoma · Locally Advanced · Sponsor: Centre Francois Baclesse
The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment
This description comes directly from the study's public registry record.
Florence LOBBEDEZ · +33231455002 · f.joly@baclesse.unicancer.fr
Romain LEVARD, MD · +33231455002 · r.levard@baclesse.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier d'Annecy | Annecy, France | Not Yet Recruiting |
| Institut Sainte Catherine | Avignon, France | Recruiting |
| Centre Hospitalier de Bayeux | Bayeux, France | Not Yet Recruiting |
| CH Boulogne sur Mer | Boulogne-sur-Mer, France | Not Yet Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Polyclinique du Parc Elsan | Caen, France | Not Yet Recruiting |
| Institut Andrée Dutreix | Coudekerque-Branche, France | Not Yet Recruiting |
| Ghpso Creil | Creil, France | Not Yet Recruiting |
| Institut de cancérologie de Bourgogne | Dijon, France | Not Yet Recruiting |
| Centre Hospitalier de Lorient | Lorient, France | Not Yet Recruiting |
| Centre Léon Bérard | Lyon, France | Not Yet Recruiting |
| Chu Montpellier | Montpellier, France | Not Yet Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07028125